Physician
OIG excluded
Rentrop, Klaus
Rentrop, Klaus was paid $1.97M by Medicaid between Jan 2018 and Aug 2023, across 26 billing codes. Its largest line is 78492, — 43% of everything it billed.
33Billing provider infoRENTROP, KLAUS
NEW YORK, NY 10001
NEW YORK, NY 10001
33aNPI1194723601assigned 07/08/2005
33bProvider typeNuclear Cardiology Physician
28Total paid$1.97M
24GClaims21,344
24DCodes billed26
24AFirst – last monthJan 2018 – Aug 2023
Compared with peers
Next to other Nuclear Cardiology Physician providers in New York
Rank by total paid#5 of 56
Median peer was paid$22K
This provider vs. median91×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
OIG exclusionListed on the federal exclusion list (09/15/2023).
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 4,062 | $707K | |
| 2019 | 5,899 | $363K | |
| 2020 | 3,588 | $336K | |
| 2021 | 5,199 | $391K | |
| 2022 | 2,131 | $140K | |
| 2023 | 465 | $37K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 78492 | 43% | 2,171 | 2,142 | $850K | |
| A9555 | Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 16% | 2,109 | 2,073 | $318K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 15% | 1,524 | 1,492 | $298K |
| 93015 | 6.2% | 4,202 | 4,054 | $122K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 4.4% | 900 | 893 | $87K |
| J2785 | Injection, regadenoson, 0.1 mg | 3.3% | 849 | 834 | $66K |
| 78431 | 3.2% | 365 | 355 | $64K | |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 2.2% | 2,226 | 2,153 | $42K |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 2.0% | 1,113 | 1,061 | $39K |
| 93925 | <1% | 224 | 224 | $12K | |
| 93880 | <1% | 304 | 304 | $11K | |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | <1% | 277 | 277 | $11K |
14 more codes
| 93923 | <1% | 184 | $11K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 719 | $9K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 316 | $7K |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 185 | $6K |
| 93224 | <1% | 164 | $6K | |
| 78434 | <1% | 343 | $3K | |
| 93922 | <1% | 134 | $3K | |
| 93970 | <1% | 82 | $3K | |
| 93000 | <1% | 440 | $2K | |
| J1245 | Injection, dipyridamole, per 10 mg | <1% | 2,092 | $2K |
| 93978 | <1% | 13 | $655.99 | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 77 | $430.22 |
| J0153 | Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | <1% | 206 | $382.47 |
| 99080 | 0% | 125 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.